Malaria Infection in Mice. Plasmodium Berghei Infection in Mice: A Model for Immune Complex Disease and Autoimmunity

1979 ◽  
pp. 647-654
Author(s):  
Lambert G. Poels ◽  
Catherine C. van Niekerk ◽  
Christoph R. Jerusalem ◽  
J. Agterberg ◽  
E. H. van Elven
Keyword(s):  
Immune Complex ◽  
Plasmodium Berghei ◽  
Malaria Infection ◽  
Complex Disease ◽  
Immune Complex Disease

scholarly journals C1q nephropathy: a true immune complex disease or an immunologic epiphenomenon?

2009 ◽  
Vol 2 (4) ◽  
pp. 285-291
Author(s):  
M. Muorah ◽  
M. D. Sinha ◽  
C. Horsfield ◽  
P. J. O'Donnell
Keyword(s):  
Immune Complex ◽  
Complex Disease ◽  
Immune Complex Disease ◽  
C1q Nephropathy

Immunopathology of Immune Complex Disease

1983 ◽  
pp. 371-390
Author(s):  
U. E. Nydegger ◽  
M. D. Kazatchkine ◽  
P. H. Lambert ◽  
P. A. Miescher
Keyword(s):  
Immune Complex ◽  
Complex Disease ◽  
Immune Complex Disease

Immunologic and clinical aspects of immune complex disease

1981 ◽  
Vol 70 (5) ◽  
pp. 1097-1106 ◽  
Author(s):  
Robert D. Inman ◽  
Noorbibi K. Day
Keyword(s):  
Immune Complex ◽  
Complex Disease ◽  
Clinical Aspects ◽  
Immune Complex Disease

scholarly journals Immunogenicity and Immune Complex Disease in Preclinical Safety Studies

2018 ◽  
Vol 46 (8) ◽  
pp. 1013-1019 ◽  
Author(s):  
John L. Vahle
Keyword(s):  
Continuing Education ◽  
Immune Complex ◽  
Complex Disease ◽  
Systemic Exposure ◽  
Clinical Pathology ◽  
Repeat Dose ◽  
Immune Complex Disease ◽  
Perivascular Inflammation ◽  
Safety Studies ◽  
Endogenous Proteins

This article summarizes a continuing education presentation on immunogenicity that was part of a continuing education course entitled, “Clinical Pathology of Biotherapeutics.” Immunogenicity of a biotherapeutic can have diverse impacts including altered systemic exposure and pharmacologic responses and, in a fraction of the cases, safety concerns including cross-reactive neutralization of endogenous proteins or sequela related to immune complex disease (ICD). In most cases, immune complexes are readily cleared from circulation; however, based on physiochemical properties, insoluble complexes form, activate complement, and deposit in tissues. Using published information and personal experience, a set of repeat-dose monkey toxicity studies with manifestations suggestive of ICD was reviewed to summarize the spectrum of clinical and pathology findings. The most common live-phase observation linked to ICD was an acute postdosing reaction following multiple dose administrations characterized by generalized collapse and attributed to acute complement activation. Less common live-phase observations were related to syndromes such as a consumptive coagulopathy or a protein losing nephropathy. The most common histologic change attributed to ICD was multi-organ vascular/perivascular inflammation followed by glomerulonephritis. The presentation concluded with a description of the challenges in assessing the relevance of immunogenicity-related reaction in monkey to human clinical use.

Sign in / Sign up

Export Citation Format

Share Document